News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|January 24, 2025

Key Strategies for Preventing CRS and ICANS

Author(s)Ryan Haumschild, PharmD, MS, MBA, CPEL, John Allan, MD, Tara Graff, MD

Panelists discuss key strategies for preventing cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) in patients receiving bispecific therapies for B-cell lymphomas.

Episodes in this series

EP. 1 ASH 2024 Updates on Bispecific Therapies in B-Cell Lymphomas

EP. 1 ASH 2024 Updates on Bispecific Therapies in B-Cell Lymphomas

EP. 2 Emerging Data for Odronextamab in DLBCL

EP. 2 Emerging Data for Odronextamab in DLBCL

EP. 3 Sequencing Consequences for Earlier Line Use of Bispecifics in B-Cell Lymphomas

EP. 3 Sequencing Consequences for Earlier Line Use of Bispecifics in B-Cell Lymphomas

EP. 4 Exploring Bispecifics in Earlier Lines of Therapy for B-Cell Lymphomas

EP. 4 Exploring Bispecifics in Earlier Lines of Therapy for B-Cell Lymphomas

EP. 5 ASH 2024 Highlights: Bispecifics in Combination Therapies for B-Cell Lymphomas

EP. 5 ASH 2024 Highlights: Bispecifics in Combination Therapies for B-Cell Lymphomas

EP. 6 MAIC Analyses and Bispecific Therapies: Guiding Treatment Decisions in B-Cell Lymphomas

EP. 6 MAIC Analyses and Bispecific Therapies: Guiding Treatment Decisions in B-Cell Lymphomas

EP. 7 Understanding CRS and ICANS: Real-World Incidence and Key Patient Risk Factors

EP. 7 Understanding CRS and ICANS: Real-World Incidence and Key Patient Risk Factors

EP. 8 Key Strategies for Preventing CRS and ICANS

EP. 8 Key Strategies for Preventing CRS and ICANS

EP. 9 Step-Up Dosing Protocols and Infection Prevention Strategies for Bispecifics in B-Cell Lymphomas

EP. 9 Step-Up Dosing Protocols and Infection Prevention Strategies for Bispecifics in B-Cell Lymphomas

EP. 10 Overcoming Logistical Hurdles in Bispecific Therapy Implementation

EP. 10 Overcoming Logistical Hurdles in Bispecific Therapy Implementation

EP. 11 Successful Implementation of Bispecific Therapies: Expert Recommendations

EP. 11 Successful Implementation of Bispecific Therapies: Expert Recommendations

EP. 12 Benefits of Implementing Bispecific Therapies in the Community

EP. 12 Benefits of Implementing Bispecific Therapies in the Community

EP. 13 Bridging the Gap: Enhancing Communication on Bispecifics Between Academic and Community Centers

EP. 13 Bridging the Gap: Enhancing Communication on Bispecifics Between Academic and Community Centers

EP. 14 Final Thoughts on Bispecifics in B-Cell Lymphomas From ASH 2024

EP. 14 Final Thoughts on Bispecifics in B-Cell Lymphomas From ASH 2024

Video content above is prompted by the following:

What are your key strategies for preventing CRS and ICANS in patients receiving bispecific therapies for B-cell lymphomas?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Trending on AJMC

CMS Final Rule Ends Federal Medicaid, CHIP Funding for Youth Gender-Affirming Care

Trump Childhood Vaccine Order: What It Means for Parents and Payers

CAR T, Bispecifics Reshape Relapsed Lymphoma Care: Madhav Seshadri, MD

Employers With Claims Data Access Take More Cost Action, Survey Finds

OCTOPUS Trial Aims to Speed Access to Rare Sarcoma Drugs